AUTHOR=Li Xinyi , He Wenfei , Zhang Xiaonan , Shu Fen , Liu Yaoxin , Tan Ning , Jiang Lei 

TITLE=Elevated α-hydroxybutyrate dehydrogenase is associated with in-hospital mortality in non-ischemic dilated cardiomyopathy

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.995899

DOI=10.3389/fcvm.2022.995899

ISSN=2297-055X

ABSTRACT=Background: Previous study found that implantation of a cardioverter-defibrillator likely caused a worse prognosis in older patients with non-ischemic systolic heart failure. This suggests that more precise risk stratification is needed in elderly patients. We conducted a retrospective study to evaluate the association of α-hydroxybutyrate dehydrogenase (α-HBDH) with mortality during hospitalization in elderly patients with non-ischemic dilated cardiomyopathy (NIDCM).
Methods: 1,019 elderly patients (age ≥60 years) diagnosed with NIDCM were retrospectively enrolled from January 2010 to December 2019. Univariate and multivariate analyses were showed to explore the relationship between α-HBDH and in- hospital death.
Results: Patients in elevated α-HBDH group (>182 U/L) had a longer hospital stays and higher in-hospital mortality. Univariate logistics regression analysis showed that elevated α-HBDH was significantly related to mortality (OR: 7.004, 95% CI: 3.583~13.693, p<0.001). Receiver operator characteristic (ROC) curve analysis reflected that α-HBDH levels had excellent predictive power for in-hospital death (AUC=0.810, 95% CI: 0.745~0.876, p<0.001). After adjustment of age, serum creatine, albumin and LVEF, multivariate regression analysis validated the association of elevated α-HBDH with increased risk of in-hospital death (p<0.05).
Conclusions: Elevated α-HBDH level is significantly related to in-hospital mortality in older patients with NIDCM.